Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | BCL2 | P10415 | 2/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15623779 | 0.92 | RAB9A (0.41) | RAB9AALDH1A1PKMMEN1KMT2A | |
| SCHEMBL542300 | 0.92 | RAB9A (0.41) | RAB9AALDH1A1PKMMEN1KMT2A | |
| SCHEMBL31259418 | 0.78 | ALDH1A1 (0.46) | ALDH1A1PKMMEN1KMT2ACHRM2 | |
| SCHEMBL3725271 | 0.77 | LMNA (0.49) | RAB9AALDH1A1KMT2ACHRM2CHRM4 | |
| SCHEMBL1514142 | 0.77 | MEN1 (0.38) | RAB9AALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL628286 | 0.77 | LMNA (0.49) | RAB9AALDH1A1KMT2ACHRM2CHRM4 | |
| SCHEMBL1514137 | 0.77 | GRIN2B (0.32) | — | |
| SCHEMBL1289807 | 0.77 | ALDH1A1 (0.37) | RAB9AALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL15106072 | 0.76 | LMNA (0.44) | RAB9AKMT2AMAPTCHRM2CHRM4 | |
| SCHEMBL8331968 | 0.76 | LMNA (0.44) | RAB9AKMT2AMAPTCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
| WO-2012046062-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | SHIRE, LLC (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | OPRM1, UGT1A6, UGT1A4 | RAB9A 707/4885ALDH1A1 327/4885PKM 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.